Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428794 | 0.87 | CA12 (0.50) | CYP2D6OPRM1CA12CA1CA2 | |
| SCHEMBL14031243 | 0.85 | CA12 (0.62) | CYP2D6OPRM1CA12CA1CA2 | |
| SCHEMBL3925930 | 0.81 | RORC (0.48) | CYP2D6 | |
| SCHEMBL3901907 | 0.81 | ALDH1A1 (0.52) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL4657165 | 0.80 | OPRM1 (0.71) | OPRM1ALDH1A1 | |
| SCHEMBL4657423 | 0.79 | OPRM1 (0.67) | CYP2D6OPRM1CA12CA1CA2 | |
| SCHEMBL18711298 | 0.78 | RORC (0.44) | CYP2D6ALDH1A1 | |
| SCHEMBL20491450 | 0.77 | RORC (0.44) | CYP2D6ALDH1A1 | |
| SCHEMBL4201312 | 0.77 | OPRM1 (0.46) | CYP2D6OPRM1ALDH1A1 | |
| SCHEMBL6888052 | 0.76 | OPRM1 (0.50) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20220088018-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
| WO-2018165520-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| EP-1549615-B1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20060241142-A1 | Naphthamide derivatives and their use | ALEATEL WIRELESS, INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1549615-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004020411-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | CYP2D6 4169/4885OPRM1 3279/4885CA12 1144/4885 |
| US-20220088018-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | CYP2D6 4169/4885OPRM1 3279/4885CA12 1144/4885 |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | CYP2D6 4169/4885OPRM1 3279/4885CA12 1144/4885 |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | CYP2D6 4169/4885OPRM1 3279/4885CA12 1144/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | CYP2D6 1409/4885OPRM1 1612/4885CA12 1023/4885 |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | CYP2D6 4169/4885OPRM1 3279/4885CA12 1144/4885 |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | CYP2D6 4169/4885OPRM1 3279/4885CA12 1144/4885 |
| US-20060241142-A1 | Naphthamide derivatives and their use | NPM1, H1-4, H1-3 | CYP2D6 170/4885OPRM1 696/4885CA12 3049/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | CYP2D6 4169/4885OPRM1 3279/4885CA12 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.